Search Results - Piamkamon Vacharotayangul
- Showing 1 - 3 results of 3
-
1
Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider by Brittany Klein, Muhammad Ali Shazib, Alessandro Villa, Fábio de Abreu Alves, Piamkamon Vacharotayangul, Stephen T. Sonis, Stefano Fedele, Nathaniel S. Treister
Published 2022Revisão -
2
Oral lichen planus: comparative efficacy and treatment costs—a systematic review by Shaiba Sandhu, Brittany Klein, Malak Al‐Hadlaq, Prazwala Chirravur, Amal Bajonaid, Yuanming Xu, Rossella Intini, Mai Hussein, Piamkamon Vacharotayangul, Hervé Sroussi, Nathaniel S. Treister, Stephen T. Sonis
Published 2022Revisão -
3
Nivolumab for Patients With High-Risk Oral Leukoplakia by Glenn J. Hanna, Alessandro Villa, Shuvro P. Nandi, R. Shi, Anne O’Neill, Mofei Liu, Charles T. Quinn, Nathaniel S. Treister, Hervé Sroussi, Piamkamon Vacharotayangul, Laura A. Goguen, Donald J. Annino, Eleni M. Rettig, Vickie Y. Jo, Kristine Wong, Patrick H. Lizotte, Cloud P. Paweletz, Ravindra Uppaluri, Robert I. Haddad, Ezra E.W. Cohen, Ludmil B. Alexandrov, William N. William, Scott M. Lippman, Sook‐Bin Woo
Published 2023Artigo
Search Tools:
Related Subjects
Medicine
Adverse effect
Cancer
Dermatology
Immunotherapy
Internal medicine
Calcineurin
Clinical endpoint
Clinical trial
Clobetasol propionate
Cochrane Library
Dysplasia
Environmental health
Gastroenterology
Immune checkpoint
Immune system
Immunology
Intensive care medicine
Nivolumab
Oncology
Oral lichen planus
Pimecrolimus
Population
Psoriasis
Randomized controlled trial
Surgery
Tacrolimus
Topical steroid
Transplantation
Triamcinolone acetonide